Medication use, tamoxifen (TAM), and TAM metabolite concentrations in women with breast cancer

Cancer Letters

Volumn 211, Issue 1, 2004, Pages 57-67

  Gallicchio, Lisa ^a   Tkaczuk, Katherine ^a   Lord, Gwyn ^b   Danton, Malcolm ^b   Lewis, Lynn M ^a   Lim, Chang K ^b   Flaws, Jodi A ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Breast cancer; Metabolism; Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; ACETYLSALICYLIC ACID; AMITRIPTYLINE; AMLODIPINE; ANTIALLERGIC AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; ANTIRHEUMATIC AGENT; ATENOLOL; ATORVASTATIN; BECLOMETASONE; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXORUBICIN; FUROSEMIDE; GLIPIZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LORATADINE; MEVINOLIN; NORTAMOXIFEN; TAMOXIFEN; TAXANE DERIVATIVE; UNINDEXED DRUG;

ADULT; AGED; ALLERGY; ARTHRITIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ANTI-ALLERGIC AGENTS; ANTICHOLESTEREMIC AGENTS; ANTIDEPRESSIVE AGENTS; ANTIHYPERTENSIVE AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRHEUMATIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MIDDLE AGED; ORGANOGOLD COMPOUNDS; TAMOXIFEN;

EID: 2942547657     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2004.04.001     Document Type: Article

References (25)

1. Furr B.J., Jordan V.C. The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther. 25:1984;127-205
2. [No authors listed], Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group, Lancet 351 (1998) 1451-1456.
3. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., Vogel V., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst. 90:1998;1371-1388
4. Mani C., Gelboin H.V., Park S.S., Pearce R., Parkinson A., Kupfer D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab. Dispos. 21:1993;645-656
5. Crewe H.K., Ellis S.W., Lennard M.S., Tucker G.T. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem. Pharmacol. 53:1997;171-178
6. Stearns V., Johnson M.D., Rae J.M., Morocho A., Novielli A., Bhargava P., et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl Cancer Inst. 95:2003;1758-1764
7. Boocock D.J., Brown K., Gibbs A.H., Sanchez E., Turteltaub K.W., White I.N. Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding of DNA. Carcinogenesis. 23:2002;1897-1901
8. Jacolot F., Simon I., Dreano Y., Beaune P., Riche C., Berthou F. Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem. Pharmacol. 41:1991;1911-1919
9. Zhao X.J., Jones D.R., Wang Y.H., Grimm S.W., Hall S.D. Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Xenobiotica. 32:2002;863-878
10. Kivisto K.T., Kroemer H.K., Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br. J. Clin. Pharmacol. 40:1995;523-530
11. Lien E.A., Anker G., Lonning P.E., Solheim E., Veland P.M. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res. 50:1990;5851-5857
12. Jones R.M., Yuan Z.X., Lamb J.H., Lim C.K. On-line high-performance liquid chromatographic-electrospray ionization mass spectometric method for the study of tamoxifen metabolism. J. Chromatogr. A. 722:1996;249-255
13. Jones R.M., Yuan Z.X., Lim C.K. Tamoxifen metabolism in rat liver microsomes: identification of a dimeric metabolite derived from free radical intermediates by liquid chromatography/mass spectrometry. Rapid Commun. Mass Spectrom. 13:1999;211-215
14. Sheth H.R., Lord G., Tkaczuk K., Danton M., Lewis L.M., Langenberg P., et al. Aging may be associated with concentrations of tamoxifen and its metabolites in breast cancer patients. J. Women Health. 12:2003;799-808
15. SAS Institute, Inc. SAS/STAT Guide for Personal Computers, Version 6.04. 1987;SAS Institute, Inc. Cary, NC
16. Flockhart D.A., Tanus-Santos J.E. Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch. Intern. Med. 162:2002;405-412
17. Chung W.G., Buhler D.R. The effect of spironolactone treatment on the cytochrome P450-mediated metabolism of the pyrrolizidine alkaloid senecionine by hepatic microsomes from rats and guinea pigs. Toxicol. Appl. Pharmacol. 127:1994;314-319
18. Heuman D.M., Gallagher E.J., Barwick J.L., Elshourbagy N.A., Guzelian P.S. Immunochemical evidence for induction of a common form of hepatic cytochrome P-450 in rats treated with pregnenolone-16 alpha-carbonitrile or other steroidal or non-steroidal agents. Mol. Pharmacol. 21:1982;753-760
19. Tang C., Shou M., Mei Q., Rushmore T.H., Rodrigues A.D. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J. Pharmacol. Exp. Ther. 293:2000;453-459
20. Miners J.O., Coulter S., Tukey R.H., Veronese M.E., Birkett D.J. Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen. Biochem. Pharmacol. 51:1996;1003-1008
21. Ma B., Prueksaritanont T., Lin J.H. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab. Dispos. 28:2000;125-130
22. Buckley M.M., Goa K.L. Tamoxifen: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs. 37:1989;451-490
23. Etienne M.C., Milano G., Fischel J.L., Frenay M., Francois E., Formento J.L., et al. Tamoxifen metabolism: pharmacokinetic and in vitro study. Br. J. Cancer. 60:1989;30-35
24. Paganini-Hill A., Clark L.J. Eye problems in breast cancer patients treated with tamoxifen. Breast Cancer Res. Treat. 60:2000;167-172
25. Flaxel C.J., Mulholland B., Haynes B. Intraocular penetration of tamoxifen. Ophthalmology. 107:2000;2006-2009